One-Year Evolution of Symptoms and Health Status of the COPD Multi-Dimensional Phenotypes: Results from the Follow-Up of the STORICO Observational Study

Figures & data

Figure 1 Disposition of patients.

Table 1 Baseline Characteristics of Analyzed Patients

	MC (n=144)	ME (n=71)	SB (n=96)	SE (n=14)	SMC (n=54)
Age (yrs) (mean±SD)	70.6±7.3	70.8±8.1	71.6±8.1	73.8±9.6	69.8±+9.1
Males (N, %)	132 (77.2)	64 (71.9)	91 (79.1)	9 (60.0)	51 (76.1)
COPD exacerbations/year (5 years before baseline) (N, %)	n=171	n=89	n=115	n=15	n=67
0–1	124 (72.5)	66 (74.2)	70 (60.9)	9 (60.0)	32 (47.8)
≥2	47 (27.5)	23 (25.8)	45 (39.1)	6 (40.0)	35 (52.2)
FEV1 of the predicted (%) (median (IQR))	67.0 (52.0–83.5)	62.1 (54.8–76.0)	63.0 (52.5–81.1)	58.5 (52.0–71.0)	55.0 (41.0–79.0)
RV (L) (median (IQR))	n=84	n=45	n=46	n=5	n=28
	2.9 (2.5–3.7)	3.9 (3.4–5.2)	2.9 (2.4–3.9)	3.0 (2.8–3.1)	2.9 (2.3–3.7)
TLC (L) (mean±SD)	n=82	n=45	n=45	n=5	n=27
	6.3±1.4	7.2±1.5	6.0±1.6	6.0±1.4	5.8±1.2
DLCO of the predicted (%) (mean±SD)	n=62	n=32	n=33	n=7	n=15
	69.7±21.2	64.3±20.9	67.4±23.5	59.5±30.5	68.3±13.6
SGRQ scores (median (IQR))	n=141	n=69	n=95	n=12	n=51
Total	21.0 (14.6–29.7)	32.8 (28.0–42.9)	32.6 (24.8–45.4)	49.0 (34.9–56.0)	53.5 (39.5–68.4)
Symptoms	24.1 (12.4–37.0)	51.1 (39.7–60.2)	45.8 (32.4–59.0)	53.3 (46.5–60.2)	70.9 (57.1–78.5)
Activity	41.1 (23.4–47.7)	48.5 (41.4–66.2)	47.7 (35.8–62.2)	66.2 (51.1–71.4)	67.1 (56.9–85.9)
Impacts	10.2 (5.0–17.8)	18.7 (13.9–28.4)	21.0 (11.4–36.3)	35.7 (20.1–47.0)	36.9 (25.2–61.9)

Note: If not otherwise specified descriptives were computed over number of patients specified in the column headings.

Abbreviations: DLCO, diffusing capacity of the lung for carbon monoxide; IQR, interquartile range; RV, residual volume; SD, standard deviation; TLC, total lung capacity; MD, mild COPD; ME, mild emphysematous; SB, severe bronchitic; SE, severe emphysematous; SMC, severe mixed COPD.

Table 2 Therapies for COPD Ongoing at Study Visits (by Multidimensional Phenotype)

	MC (n=144)	ME (n=71)	SB (n=96)	SE (n=14)	SMC (n=54)
Baseline (n, %)
Triple therapy	40 (27.8)	27 (38.0)	44 (45.8)	3 (21.4)	19 (35.2)
LABA+LAMA	39 (27.1)	22 (31.0)	20 (20.8)	4 (28.6)	18 (33.3)
LAMA Alone	35 (24.3)	11 (15.5)	12 (12.5)	1 (7.1)	8 (14.8)
ICS+LABA	22 (15.3)	6 (8.5)	16 (16.7)	5 (35.7)	7 (13.0)
Other	8 (5.5)	5 (7.0)	4 (4.1)	1 (7.1)	2 (3.7)
6-month follow-up (n, %)
Triple therapy	39 (27.1)	27 (38.0)	45 (46.9)	4 (28.6)	19 (35.2)
LABA+LAMA	42 (29.2)	23 (32.4)	21 (21.9)	5 (35.7)	19 (35.2)
LAMA Alone	34 (236)	12 (16.9)	10 (10.4)	1 (7.1)	7 (13.0)
ICS+LABA	21 (14.6)	5 (7.0)	16 (16.7)	3 (21.4)	8 (14.8)
Other	8 (5.5)	4 (5.6)	4 (4.1)	1 (7.1)	1 (1.9)
12-month follow-up (n, %)
No ongoing therapies	1 (0.7)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)
Triple therapy	38 (26.4)	26 (36.6)	46 (47.9)	4 (28.6)	19 (35.2)
LABA+LAMA	43 (29.9)	23 (32.4)	20 (20.8)	5 (35.7)	19 (35.2)
LAMA Alone	33 (22.9)	12 (16.9)	11 (11.5)	1 (7.1)	7 (13.0)
ICS+LABA	21 (14.6)	6 (8.5)	16 (16.7)	3 (21.4)	8 (14.8)
Other	8 (5.5)	4 (5.6)	3 (3.1)	1 (7.1)	1 (1.9)

Notes: Percentages were computed over number of patients specified in the column headings. Triple therapy is any combination of ICS, LAMA and LABA in fixed dose combination or not; Other: SABA, LABA Alone, ICS+LABA, ICS+SABA, ICS+LAMA.

Abbreviations: ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; LAMA, long-acting muscarinic agonists; SAMA, short-acting muscarinic antagonist; SABA, short-acting β2-agonists; MD, mild COPD; ME, mild emphysematous; SB, severe bronchitic; SE, severe emphysematous2; SMC, severe mixed COPD.

Figure 2 (A) Frequency of patients with COPD symptoms by multidimensional phenotype at baseline. (B) Frequency of patients with COPD symptoms by multidimensional phenotype at 6-month follow-up. (C) Frequency of patients with COPD symptoms by multidimensional phenotype at 12-month follow-up.

Table 3 1-Year Evolution of COPD Symptoms (by Multidimensional Phenotype)

	MC (n=144)	ME (n=71)	SB (n=96)	SE (n=14)	SMC (n=54)	p-value
Night-time symptoms evolution (n, %)
Between baseline and 6-month follow-up
Arising	12 (8.3)	9 (12.7)	0 (0.0)	0 (0.0)	0 (0.0)	<0.0001
Always absent	128 (88.9)	52 (73.2)	0 (0.0)	0 (0.0)	0 (0.0)
Always present	3 (2.1)	6 (8.5)	69 (71.9)	7 (50.0)	41 (75.9)
No more present	1 (0.7)	4 (5.6)	27 (28.1)	7 (50.0)	13 (24.1)
Between 6-month and 12-month follow-up
Arising	9 (6.3)	2 (2.8)	10 (10.4)	1 (7.1)	4 (7.4)	<0.0001
Always absent	120 (83.3)	54 (76.1)	17 (17.7)	6 (42.9)	9 (16.7)
Always present	8 (5.6)	7 (9.9)	54 (56.3)	5 (35.7)	39 (72.2)
No more present	7 (4.9)	8 (11.3)	15 (15.6)	2 (14.3)	2 (3.7)
EARLY-MORNING symptoms evolution (n, %)
Between baseline and 6-month follow-up
Arising	11 (7.6)	5 (7.0)	2 (2.1)	0 (0.0)	1 (1.9)	<0.0001
Always absent	57 (39.6)	0 (0.0)	8 (8.3)	0 (0.0)	0 (0.0)
Always present	64 (44.4)	60 (84.5)	79 (82.3)	10 (71.4)	51 (94.4)
No more present	12 (8.3)	6 (8.5)	7 (7.3)	4 (28.6)	2 (3.7)
Between 6-month and 12-month follow-up
Arising	11 (7.6)	4 (5.6)	5 (5.2)	2 (14.3)	2 (3.7)	<0.0001
Always absent	58 (40.3)	2 (2.8)	10 (10.4)	2 (14.3)	0 (0.0)
Always present	57 (39.6)	62 (87.3)	69 (71.9)	7 (50.0)	49 (90.7)
No more present	18 (12.5)	3 (4.2)	12 (12.5)	3 (21.4)	3 (5.6)
DAY-TIME symptoms evolution (n, %)
Between baseline and 6-month follow-up
Arising	12 (8.3)	1 (1.4)	5 (5.2)	0 (0.0)	1 (1.9)	<0.0001
Always absent	60 (41.7)	0 (0.0)	6 (6.3)	0 (0.0)	1 (1.9)
Always present	59 (41.0)	63 (88.7)	76 (79.2)	11 (78.6)	50 (92.6)
No more present	13 (9.0)	7 (9.9)	9 (9.4)	3 (21.4)	2 (3.7)
Between 6-month and 12-month follow-up
Arising	12 (8.3)	3 (4.2)	5 (5.2)	0 (0.0)	3 (5.6)	<0.0001
Always absent	61 (42.4)	4 (5.6)	10 (10.4)	3 (21.4)	0 (0.0)
Always present	53 (36.8)	61 (85.9)	70 (72.9)	9 (64.3)	48 (88.9)
No more present	18 (12.5)	3 (4.2)	11 (11.5)	2 (14.3)	3 (5.6)

Note: Percentages were computed over number of patients specified in the column headings.

Abbreviations: MD, mild COPD; ME, mild emphysematous; SB, severe bronchitic; SE, severe emphysematous; SMC, severe mixed COPD.